Form 4: Atossa Therapeutics CEO Steven Quay Acquires Additional Shares

Atossa Therapeutics' CEO, Steven Quay, recently purchased 11,239 shares of common stock at an average price of $0.8797 per share.

Summary

• On May 21, 2025, Steven C. Quay, the President and CEO of Atossa Therapeutics, acquired 11,239 shares of Atossa Therapeutics common stock.
• The shares were purchased at a weighted average price of $0.8797, with individual prices ranging from $0.8794 to $0.9100.
• Following the transaction, Quay directly owns 13,898 shares of Atossa Therapeutics common stock.
• Quay also has indirect ownership of 22,254 shares through Ensisheim Partners, LLC, an entity he co-owns with Dr. Shu-Chih Chen.
• Quay disclaims beneficial ownership of the shares held by Ensisheim Partners, LLC except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The CEO's purchase is a positive sign, but it's a relatively small transaction. The disclaimer of beneficial ownership of shares held by Ensisheim Partners, LLC adds a layer of complexity.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Management Comments

• The Reporting Person will provide full information regarding the number of shares purchased at each separate price upon request by the SEC, the Issuer, or a security holder of the Issuer.
• The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

Insider trading activity is closely monitored as it can provide insights into a company's performance and future prospects. Form 4 filings are a standard part of regulatory compliance for company insiders.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders, including CEOs, to report transactions in their company's stock.
• The reporting requirements are consistent across all publicly traded companies and are enforced by the SEC.
• Comparing the frequency and size of insider transactions at Atossa Therapeutics to similar biotech companies can provide insights into management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Atossa Therapeutics, Steven Quay, stock purchase, Form 4, insider trading, common stock, Ensisheim Partners, beneficial ownership